Furthermore, anti-myeloma regimens including combinations of proteasome inhibitors (bortezomib, ixazomib, carfilzomib) with either an anti-CD38 monoclonal antibody (daratumumab) or an immunomodulatory drug (lenalidomide, thalidomide) seem to improve indices of bone metabolism [45]. The gene discussed is CD38; the disease is plasma cell myeloma.